PRA Strengthens Psychiatry Capabilities

Dr. Frederick Lewis Joins Therapeutic Expertise Group

News provided by

Aug 19, 2011, 09:00 ET

RALEIGH, N.C., Aug. 19, 2011 /PRNewswire-FirstCall/ -- PRA, a leading Clinical Research Organization, announces the hiring of Dr. Frederick T. Lewis, D.O. as Vice President, Psychiatry – Scientific Affairs in our Therapeutic Expertise group. Dr. Lewis will provide medical and scientific support for PRA project teams and guidance to clients in all aspects of clinical drug development.

"Dr. Lewis's exceptional background in psychiatry and broad-ranging industry experience make him an ideal fit for our Therapeutic Expertise group," said Dr. Michael Kirchengast, Vice President and head of PRA's Scientific Affairs department. "Adding Fred to our team of experts strengthens our ability to provide comprehensive strategic consultancy for our clients' projects."

Dr. Lewis has more than 20 years of research and professional experience in psychiatry. A graduate of the Pennsylvania State University and the Southeastern College of Osteopathic Medicine, his post-residency experience includes multiple fellowships. Dr. Lewis maintains an appointment as an associate professor at Nova Southeastern University's College of Osteopathic Medicine, where he chaired the psychiatry department from 1996 to 2003.

Dr. Lewis has received numerous awards, including The President's Award for Research by Nova Southeastern University. He has served as a consultant and scientific advisor for several pharmaceutical companies and was an original founder of CNS Clinical Research, Inc. Dr. Lewis has been an investigator in numerous clinical trials and authored many publications in the area of psychopharmacology.

PRA's Scientific Affairs provides access to scientific, therapeutic, drug development and regulatory expertise, which drive the company's service offerings. Our team of experts facilitates rapid access to investigators, health organizations and patients worldwide. Their relationships with key opinion leaders, regulators, academics and patient advocacy groups form a strong network across the globe.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email [email protected] or call our Global Headquarters.

SOURCE PRA